Literature DB >> 32169226

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D Planchard1, S Popat2, K Kerr3, S Novello4, E F Smit5, C Faivre-Finn6, T S Mok7, M Reck8, P E Van Schil9, M D Hellmann10, S Peters11.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32169226     DOI： 10.1093/annonc/mdy275

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  85 in total

1.  Serum protein level as a predictor of therapeutic response and adverse effects associated with afatinib use.

Authors:  Wang Chun Kwok; James Chung Man Ho; Terence Chi Chun Tam; Mary Sau Man Ip; David Chi Leung Lam
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

2.  Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study.

Authors:  Montse Alemany; Marta Domènech; Andreas A Argyriou; Noelia Vilariño; Carles Majós; Pablo Naval-Baudin; Anna Lucas; Ramón Palmero; Marta Simó; Ernest Nadal; Jordi Bruna
Journal:  Ann Transl Med       Date:  2021-04

3.  Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 4.  Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review.

Authors:  Zhe Zhang; Sen Yang; Yanfang Ma; Hanqiong Zhou; Xuan Wu; Jing Han; Jiabao Hou; Lidan Hao; Jonathan D Spicer; Young Wha Koh; Mariano Provencio; Noemi Reguart; Tetsuya Mitsudomi; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2021-06

5.  Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells.

Authors:  Liyuan Yin; Yi Zhang; Lijuan Yin; Yan Ou; Michael S Lewis; Ruoxiang Wang; Haiyen E Zhau; Qinghua Zhou; Leland W K Chung
Journal:  Mol Cancer Ther       Date:  2021-09-28       Impact factor: 6.009

6.  Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist.

Authors:  Yongjie Yang; Jingli Lu; Yanfang Ma; Chen Xi; Jian Kang; Qiwen Zhang; Xuedong Jia; Kefeng Liu; Shuzhang Du; Florian Kocher; Andreas Seeber; Cesare Gridelli; Mariano Provencio; Nobuhiko Seki; Yusuke Tomita; Xiaojian Zhang
Journal:  Transl Lung Cancer Res       Date:  2021-06

7.  Lin28A promotes the proliferation and stemness of lung cancer cells via the activation of mitogen-activated protein kinase pathway dependent on microRNA let-7c.

Authors:  Rui Zhang; Pengpeng Liu; Xiao Zhang; Yingnan Ye; Jinpu Yu
Journal:  Ann Transl Med       Date:  2021-06

8.  First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.

Authors:  Francesco Facchinetti; Massimo Di Maio; Fabiana Perrone; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2021-06

9.  Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay.

Authors:  Simon Heeke; Jonathan Benzaquen; Audrey Vallee; Maryline Allegra; Julien Mazieres; Julien Fayada; Jaya Rajamani; Michael Lee; Ellen Ordinario; Angelica Tiotiu; Jacques Cadranel; Michel Poudenx; Denis Moro-Sibilot; Fabrice Barlesi; Radj Gervais; Juliette Thariat; Virginie Tanga; Jacques Boutros; Marius Ilié; Véronique Hofman; Charles-Hugo Marquette; Marc G Denis; Paul Hofman
Journal:  Ann Transl Med       Date:  2021-06

Review 10.  New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature.

Authors:  Hao Li; Taorui Liu; Zewen Sun; Zhenfan Wang; Xianping Liu; Fan Yang
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.